Search clinical trials for: Octreotide LAR (Long-acting release)

Total 6006 results

Novartis Pharmaceuticals

Completed

Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea (LARCID)

Chemotherapy-induced Diarrhea

Brazil
Carmen Schade-Brittinger

Completed

Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

Neuroendocrine Tumors

Germany
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Completed

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

Neuroendocrine Carcinoma | Islet Cell Carcinoma

United States
Mayo Clinic

Completed

Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis

Cirrhosis | Portal Hypertension | Esophageal Varices
Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
Sinotau Pharmaceutical Group

Recruiting

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Neuroendocrine Tumors

China
Azidus Brasil

Suspended

Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®

Acromegaly

Brazil
Federico II University
University of Genova; University Hospital, Udine, Italy; University of Perugia...

Completed

High Dose Somatostatin Analogues in Neuroendocrine Tumors (HIDONET)

Gastrointestinal Neoplasms | Respiratory Tract Neoplasms | Pancreatic Neoplasms | Multiple Endocrine Neoplasia | Thymic Neoplasms

Italy
Peking University

Unknown

Octreotide LAR as Maintenance Treatment for Patients With NEC

Esophageal Neuroendocrine Carcinoma | Gastro-entero-pancreatic Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Advanced Gastroenteropancreatic Neuroendocrine Tumor

China
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Terminated

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Neuroendocrine Carcinoma

United States
Ambrilia Biopharma, Inc.

Completed

Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

Acromegaly

Belarus, Hungary, Romania, Serbia, Slovakia, Ukraine
Cedars-Sinai Medical Center
Novartis Pharmaceuticals

Completed

Ultrasound Guided Octreotide LAR Injection in Acromegaly

Acromegaly

United States
Ipsen

Terminated

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Malignant Carcinoid Syndrome

United States
Cliniques universitaires Saint-Luc- Université...

Terminated

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation (SCIROCCO)

Neuroendocrine Tumors | Carcinoid Syndrome
Novartis

Completed

Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients

Prostate Cancer

Italy
Mario Negri Institute for Pharmacological Research

Recruiting

Outcome of ADPKD With Octreotide LAR (ADPKD648)

Autosomal Dominant Polycystic Kidney

Italy
Novartis

Completed

Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

Acromegaly
Federico II University

Completed

Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly (HDacro)

Acromegaly

Italy
University of Turin, Italy

Completed

5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors

Neuroendocrine Tumors

Italy
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly

Acromegaly
Virginia Commonwealth University
Novartis; Thoratec Corporation

Completed

Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)

Gastrointestinal Bleeding

United States
NYU Langone Health

Completed

Surgical Debulking of Pituitary Adenomas

Pituitary Adenoma

United States
Changhai Hospital

Completed

Real-world Study on Adjuvant Octreotide Therapy in pNETs

Pancreatic Neuroendocrine Tumor G2
Chengfeng Wang

Unknown

The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical Trial

Pancreatic Diseases

China
Novartis Pharmaceuticals

Approved for marketing

An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly (ACCESS)

Acromegaly

United States
Federico II University

Completed

Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly (GLUSSA)

Acromegaly

Italy
Asan Medical Center
Novartis Korea Ltd.

Unknown

Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues (acromegaly)

Acromegaly

Korea, Republic of
Federico II University

Completed

Prediction of Tumor Shrinkage in Acromegaly

Acromegaly

Italy
Lexicon Pharmaceuticals

Completed

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Carcinoid Syndrome

United States
Mario Negri Institute for Pharmacological Research

Completed

Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency (ALADIN2)

Autosomal Dominant Polycystic Kidney Disease

Italy
Novartis

Terminated

Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.

Proliferative Diabetic Retinopathy

Switzerland
Grupo Espanol de Tumores Neuroendocrinos

Completed

Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET (EVERLAR)

Gastrointestinal Neoplasms

Spain
Federico II University
Ospedali dei Colli

Completed

GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma (SS-HCC)

Advanced Hepatocellular Carcinoma

Italy
Radboud University Medical Center
Novartis

Completed

Everolimus and LongActing Octreotide Trial in Polycystic Livers (ELATE)

Polycystic Liver Disease

Netherlands
Pfizer

Completed

Pegvisomant And Sandostatin LAR Combination Study

Acromegaly

Canada, United States, Germany, Italy, United Kingdom, Norway, Australia, Spain, Brazil, Mexico, France, Netherlands
Odense University Hospital

Completed

Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction

Acromegaly

Denmark
Hospices Civils de Lyon

Completed

Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment (SOMILEO)

Enterostomy

France
Peking University People's Hospital

Completed

Efficacy of Ultrasound-guided Transverse Carpal Ligament Release for Carpal Tunnel Syndrome

Carpal Tunnel Syndrome

China
Camurus AB

Active, not recruiting

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (SORENTO)

Gastro-enteropancreatic Neuroendocrine Tumor

United States, Belgium, Spain, Netherlands, France, Germany, Israel, Italy, Canada, Australia, Romania, Hungary
Mayo Clinic
Novartis; National Center for Research Resources (NCRR)

Completed

Octreotide in Severe Polycystic Liver Disease

Liver Diseases | Abdominal Pain | Polycystic Kidney, Autosomal Dominant | Hepatomegaly | Polycystic Liver Disease | Kidney, Polycystic

United States
Chemi S.p.A.

Completed

Extended-release of Octreotide (LF-PB) for the Treatment of Seroma

Seroma

Italy
Advanced Accelerator Applications

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2)

Gastro-enteropancreatic Neuroendocrine Tumor

Spain, United States, United Kingdom, France, Canada, Germany, Netherlands, Italy, Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals; RECORDATI GROUP

Completed

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Neuroendocrine Tumors | Carcinoid Tumors

United States
Novartis Pharmaceuticals

Completed

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Peritoneal Neoplasms | Intestinal Obstruction | Carcinomatosis

France
Novartis Pharmaceuticals

Completed

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

Acromegaly

Italy
Cedars-Sinai Medical Center

Terminated

Acromegaly Combination Treatment Study

Acromegaly

United States
Mario Negri Institute for Pharmacological Research
Otsuka Pharmaceutical Italy S.r.l.

Completed

Tolvaptan-Octreotide LAR Combination in ADPKD (TOOL)

Autosomal Dominant Polycystic Kidney Disease

Italy
Debiopharm International SA

Active, not recruiting

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01)

Acromegaly | GEP-NET

United Kingdom, France, Spain, Italy, Poland, Denmark, Germany, Israel
Novartis Pharmaceuticals

Completed

Pediatric Hypothalamic Obesity

Obesity

United States

Search clinical trials for: Octreotide LAR (Long-acting release)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations